[{"orgOrder":0,"company":"Petrovax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Azoximer Bromide","moa":"polymers","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Petrovax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Petrovax \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Petrovax \/ Undisclosed"},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Russian Direct Investment Fund","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Russian Direct Investment Fund \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Russian Direct Investment Fund \/ Undisclosed"},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Russian Direct Investment Fund","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Russian Direct Investment Fund \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Russian Direct Investment Fund \/ Undisclosed"},{"orgOrder":0,"company":"Avva Rus JSC","sponsor":"Kirov State Medical Academy | Kirov Regional Clinical Center of Perinatology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Probiotic","year":"2010","type":"Inapplicable","leadProduct":"Lactofiltrum","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Avva Rus JSC","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Avva Rus JSC \/ Kirov State Medical Academy | Kirov Regional Clinical Center of Perinatology","highestDevelopmentStatusID":"9","companyTruncated":"Avva Rus JSC \/ Kirov State Medical Academy | Kirov Regional Clinical Center of Perinatology"},{"orgOrder":0,"company":"Avva Rus JSC","sponsor":"St. Vladimir Moscow Children's Clinical Hospital | Arhangelsk Regional Children's Clinical Hospital named after Vizshletsov P.G.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Lignin Hydrolytic","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Avva Rus JSC","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Avva Rus JSC \/ St. Vladimir Moscow Children's Clinical Hospital | Arhangelsk Regional Children's Clinical Hospital named after Vizshletsov P.G.","highestDevelopmentStatusID":"9","companyTruncated":"Avva Rus JSC \/ St. Vladimir Moscow Children's Clinical Hospital | Arhangelsk Regional Children's Clinical Hospital named after Vizshletsov P.G."}]